Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury

Drug

Standing/walking/mobility

Online since 11 November 2022, updated 642 days ago

About this trial

This phase 1/phase 2 trial is enrolling individuals with incomplete chronic cervical and thoracic spinal cord injuries to test the effect of a drug (Rimonabant) on walking ability. If included, participants will either take: 1) two pills of placebo; 2) one pill of placebo and one pill of Rimonabant (2.5mg); or 3) two pills of Rimonabant (5mg) once per day for 5 consecutive days. Final testing will be performed after 15 days.

Included participants

Gender

All

Age

18 - 65 years

Injury level

C4 - L1

Severity (AIS)?

AIS-D

Time since injury

≥ 1 year

Injury type

Traumatic

Healthy volunteers

C4-L1

Additionally, participants must

Have an assessable level of walking ability (with or without walking aid)

What’s involved

Type

Drug

Details

Participants will receive either 1) two pills of placebo, 2) one pill of placebo and one pill of Rimonabant (2.5mg) or 3) two pills of Rimonabant once per day on 5 consecutive days.

Potential benefits

Main benefits

Standing/walking/mobility

Additional benefits

General health

Mental health and psychosocial factors

Pain

Spasticity

Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

Wings for Life supports SCITrialsFinder

Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

Learn more

Back to results